

# ADVAC 2026

## DRAFT PROGRAM

### AS OF 21 APRIL 2026

## MONDAY 11 MAY 2026

<b>TBC</b>	Bus from hotels to Les Pensières		
<b>9:00-9:30</b>	Opening and Objectives of the course	<b>Kamel Senouci</b> , Director ADVAC, University of Geneva	Charles Mérieux conf. room
<b>9:30-9:40</b>	Welcome and Logistic briefing	<b>Sandra Angèle</b> , Director, Les Pensières, Fondation Mérieux	
<b>SESSION 1: THE VACCINE JOURNEY: FROM VACCINES TO VACCINATION &amp; THE IMPACT OF VACCINES</b>			<b>Chair: Arnaud Didierlaurent</b> , University of Geneva
<b>9:40-10:05</b>	<b>1. From Research to individual protection: The A-to-Z vaccine's journey</b>	<b>Arnaud Didierlaurent and Kamel Senouci</b> , University of Geneva, Switzerland	Charles Mérieux conf. room
<b>10:05-10:25</b>	Discussion		
<b>10:25-10:55</b>	Break		Restaurant
<b>10:55-11:20</b>	<b>2. Vaccines Preventable Diseases' Burden and Vaccines Impact on Public Health</b>	<b>Kamel Senouci</b> , University of Geneva	
<b>11:20-11:40</b>	Discussion		
<b>11:40-12:05</b>	<b>3. Measuring vaccination's impact in populations</b>	<b>Brad Gessner</b> , Independent expert	Charles Mérieux conf. room
<b>12:05-12:25</b>	Discussion		
<b>12:25-12:35</b>	Morning evaluations		
<b>12:35-13:35</b>	Lunch (seated, please check the tables attributed to the speakers)		Restaurant + Ogobara Doumbo room
<b>13:35-14:00</b>	<b>4. Where are we with vaccine-preventable diseases &amp; immunization coverage worldwide: the state of the immunization</b>	<b>Kate O'Brien</b> , WHO, Geneva	
<b>14:00-14:20</b>	Discussion		
<b>14:20-14:45</b>	<b>5. Using vaccines to address a public health problem: the example of Polio eradication immunization strategy</b>	<b>Ananda Bandyopadhyay</b> , Gates Foundation, USA	Charles Mérieux conf. room
<b>14:45-15:05</b>	Discussion		
<b>15:05-15:30</b>	<b>6. GAVI model to support countries immunization program</b>	<b>Marta Tufet</b> , GAVI	
<b>15:30-15:50</b>	Discussion		
<b>15:50-16:00</b>	Afternoon evaluations		
<b>16:00-16:30</b>	Break		Restaurant
<b>16:30-17:15</b>	<b>Meet your mentor</b>		<b>TBC</b>
<b>17:15-18:15</b>	Self-presentation of participants (background, interests in life...)	Social Event	Nicole Mérieux room
<b>18:15-20:00</b>	Welcome Reception		Nicole Mérieux room + Terrasse
<b>20:15</b>	Bus to Hotels		

# TUESDAY 12 MAY 2026

**TBC** Bus from hotels to Les Pensières

## SESSION 2: HOW VACCINES WORK?

Chair:  
Kamel Senouci,  
Director  
ADVAC, UNIGE

09:00-09:25	<b>7. How do vaccines protect?</b> Immune effectors induced by vaccines: Antibodies, B and T cells, mucosal immunity	<b>Christiane Eberhardt</b> , University of Geneva, Switzerland	
09:25-09:45	Discussion		
09:45-10:10	<b>8. How are vaccines' responses elicited?</b> What a vaccinologist should know about the basic aspects of immunological responses	<b>Christiane Eberhardt</b> , University of Geneva, Switzerland	Charles Mérieux conf. room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	<b>9. How to use vaccines' platforms to tailor immune responses?</b>	<b>Arnaud Didierlaurent</b> , University of Geneva, Switzerland	
11:25-11:45	Discussion		
11:45-12:10	<b>10. Use and limitations of correlates of immunity in vaccinology</b>	<b>Adam Finn</b> , University of Bristol, UK	Charles Mérieux conf. room
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo room
14:00-15:30	<b>Interactive Session 1 and Q&amp;A</b> <b>Variability of vaccine responses in the real world</b>	<b>Christiane Eberhardt</b> , University of Geneva, Switzerland & <b>Arnaud Didierlaurent</b> , University of Geneva, Switzerland	Charles Mérieux + Simone Mérieux
15:30-15:55	<b>11. Immunological memory</b>	<b>Rafi Ahmed</b> , Emory University, USA	
15:55-16:15	Discussion		Charles Mérieux
16:15-16:45	Break		Restaurant
16:45-17:10	<b>12. Non-specific effects of vaccines</b>	<b>Nigel Curtis</b> , The Royal Children's Hospital, Melbourne, Australia	Charles Mérieux
17:10-17:30	Discussion		

## SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 1/3)

Chair: Arnaud Didierlaurent

17:30-17:55	<b>13. Vaccine market, market shaping and regional initiatives for vaccine production</b>	<b>Georgios Stathopoulos</b> , WHO, Switzerland	
17:55-18:15	Discussion		Charles Mérieux
18:15-18:25	Afternoon evaluations		
18:25-19:30	Soccer, Karaoke, Mölkky, Pétanque....	Social Event	Outside
19:45-21:00	Drinks and Dinner		<b>TBC</b>
21:00	Bus to Hotels		

# WEDNESDAY 13 MAY 2026

TBC

Bus from hotels to Les Pensières

## SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 2/3)

Chair: Arnaud Didierlaurent  
± E. Erbeling,

09:00-09:25	14. Landscape in vaccine and immunization technologies- platform-production (include nasal vaccine)	Emily Erbeling (Independent expert)	
09:25-09:45	Discussion		Charles Mérieux
09:45 -10:10	15. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger, IAVI, USA	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	16. From inception to regulatory submission	Rick Malley, Boston Children Hospital, USA	
11:25-11:45	Discussion		
11:45-12:10	17. The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, France	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-13:55	Lunch		Restaurant + O. Doumbo

## SESSION 4 – VACCINE REGULATORY

Chair: E. Erbeling

13:55-14:20	18. The role of Regulatory Agencies, Issues and Challenges of submitting a dossier (including content of a dossier)	Marco Cavaleri, EMA, The Netherlands	Charles Mérieux Room
14:20-14:40	Discussion		
14:40-16:10	<b>Small Group Exercise 1 (Part 1): Vaccine Regulatory</b> <b>4 Groups:</b> <ul style="list-style-type: none"> <li>○ 1. Ozzie Berger &amp; Luis Jodar</li> <li>○ 2. Arnaud Didierlaurent &amp; Veronica Gambillara-Fonck</li> <li>○ 3. Olga Rovira &amp; Norman Baylor</li> <li>○ 4. Marco Cavaleri &amp; Donna Boyce</li> <li>○</li> </ul>	<b>Norman Baylor</b> , Biologics Consulting Group, US <b>Ozzie Berger</b> , IAVI, USA, <b>Donna Boyce</b> , Pfizer USA, <b>Marco Cavaleri</b> , EMA, Netherland, <b>Arnaud Didierlaurent</b> , UNIGE, Switzeland, <b>Veronica Gambillara-Fonck</b> , Pureos Bioventures, Switzerland, <b>Luis Jodar</b> (independent expert), <b>Olga Rovira</b> , Kontivax, Belgium.	Different rooms
16:10-16:40	Break		Restaurant
16:40-16:55	Small Group Exercise 1 (Part 2): Debriefing	All groups	Charles Mérieux Room
16:45-18:15	<b>Optional lecture: Interactive Session 2</b>  <b>From ideas to implementation</b> - the realities of funding for vaccine research and development in the private sector  <b>Please check group assignments on boards</b>	DCVMN and IFPMA members	Charles Mérieux Room + S.Mérieux Room
18:15-18:25	Afternoon evaluations		Charles Mérieux Room

## Special lecture: THE 10<sup>th</sup> LAMBERT LECTURE

18:25-18:35	Introduction	Paul-Henri Lambert	
18:35-19:00	19. Immune Fitness	John S. Tsang, Yale University, USA	Charles Mérieux room
19:00-19:20	Discussion		
19:20-	Dinner		

21:00 Bus to Hotels

## THURSDAY 14 MAY 2026

**TBC** Bus from hotels to Les Pensières

### SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 3/3)

Chair: Emily Erbelding

09:00-09:25 20. Delivering outbreaks vaccine in 100 Days: What does it take? Aurelia Nguyen, CEPI, UK

09:25-09:45 Discussion

09:45-10:45 Interactive session 3 and Q&A

What can go wrong in vaccine development?

Panelists:

Rosane Cuber, Bio-Manguinhos, Brazil  
Luis Jodar (independent expert)  
Rick Malley, Boston Children Hospital, USA  
Emily Erbelding (independent expert)  
Adam Finn, University of Bristol, UK

Charles Mérieux  
Conf room

10:45-11:00 Break

Restaurant

### SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)

Chair: Edwin Asturias

11:00-11:25 21. Clinical trials: an overview of issues to be considered Andrew Pollard, Oxford Vaccine Group, UK

11:25-11:45 Discussion

11:45-12:10 22. Introduction to statistical aspects of clinical trials Martha Nason, PATH, USA

12:10-12:30 Discussion

12:30 -12:40 Morning Evaluations

12:40-13:10 Working lunch: Participants eat at the Restaurant with their group and go back to their room for the SGE 2

Restaurant

13:10-15:25 Small Group Exercise 2:

How to design, recruit volunteers for, and analyze the results of selected phase II trials

7 Groups:

Group 1: S. Aureus: V. Gambillara & B. Gessner  
Group 2: Ebola: M. Nason & R. Libster  
Group 3: Dengue: N. Baylor & A. Durbin  
Group 4: RSV: E. Asturias & K. Talaat  
Group 5: Mpox: K. Johansen  
Group 6: Typhoid conjugate vaccines: K. Senouci  
Group 7: Coronavirus: E. Erbelding

Check Group assignment and rooms on boards

15:25-15:50 23. Assessing herd protection and vaccine effectiveness (and use for licensure) John Clemens, International Vaccine Institute (IVI), Republic of Korea

Charles Mérieux

15:50-16:10 Discussion

16:10-16:40 Break

Restaurant

16:40-17:05 24. A to Z for vaccines clinical trials Romina Libster, Fundacion INFANT, Argentina

17:05-17:25 Discussion

17:25-17:50 25. Human Challenge Trials or other ways of assessing vaccine efficacy Chris Chiu, Imperial College London, UK

17:50-18:10 Discussion

Charles Mérieux

18:10-18:20 Afternoon evaluations

18:20-19:40 Dinner

Restaurant + O.Doumbo room

19:45 Bus to Hotels

# FRIDAY 15 MAY 2026

TBC

Bus from hotels to Les Pensières

**Chair:** Kari Johansen

## SESSION 6 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS

09:00-09:25	<b>26. How do vaccines cause adverse events?</b> (Including Immune-mediated diseases)	<b>Kawsar Talaat</b> , Johns Hopkins Bloomberg School of Public Health, USA	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	<b>27. WHO Guidance on how to detect and manage safety issues</b>	<b>Madhav Balakrishnan</b> , WHO, Switzerland	Conf room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	<b>28. Population-based post-licensure surveillance</b> (including study methodology for signal validation and epi studies)	<b>Kaatje Bollaerts</b> , P95, Belgium	
11:25-11:45	Discussion		Charles Mérieux
11:45-12:10	<b>29. Immunization safety, logistic and vaccine management in vaccination programs (CTC, VVM)</b>	<b>Kamel Senouci</b> , University of Geneva	
12:10-12:30	Discussion		
12:30-12:40	Morning Evaluations		
12:40-14:00	Lunch		Restaurant + Ogobara Doumbo

## SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)

14:00-14:30	Mentoring		
14:30-16:40	<b>Small group exercise 3:</b> <b>Vaccine trial Phase III planning, implementation, analysis of the study results</b>	<b>7 Groups:</b> <b>Group 1:</b> V. Gambillara <b>Group 2:</b> M. Nason & R. Libster <b>Group 3:</b> N. Baylor & A. Durbin <b>Group 4:</b> E. Asturias & K. Talaat <b>Group 5:</b> K. Johansen <b>Group 6:</b> K. Senouci <b>Group 7:</b> E. Erbeling	Charles Mérieux O. Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr
16:40-16:50	Afternoon evaluations		
16:50-17:20	Break		Restaurant

## Special lecture: THE 18<sup>TH</sup> PLOTKIN LECTURE

17:20-17:25	<b>Introduction</b>	<b>Edwin Asturias</b> , Children's Hospital Colorado, USA	
17:25-17:50	<b>30. Advancing CMV Vaccine Strategies: From Bench to Bedside</b>	<b>Sallie Permar</b> , Cornell University, USA	Charles Mérieux
17:50-18:10	Discussion		
18:10-20:00	Reception Dinner		Restaurant + O. Doumbo
20:00	Bus to Les Pensières		

## SATURDAY 16 MAY 2026

**TBC** Bus from hotels to Les Pensières

### SESSION 7 - ETHICAL ISSUES

**Chair: Kari Johansen**, Public Health Agency, Sweden

09:00-09:25	<b>31. Applied ethics in immunization programs and practice</b>	<b>Anuradha Rose</b> , Christian Medical College of Vellore, India	
09:25-09:45	Discussion		Charles Mérieux conf room
09:45-10:10	<b>32. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines</b>	<b>Catherine Slack</b> , University of KwaZulu-Natal, South Africa	
10:10-10:30	Discussion		
10:30-10:50	Break		Restaurant
10:50-13:00	<b>Small group exercise 4: Ethical considerations in vaccine trials</b>	<b>Facilitators (7 Groups): Edwin Asturias, Kari Johansen, Anuradha Rose, Louise Henaff, Catherine Slack, Martha Nason, Kawsar Talaat.</b>	Check rooms' assignments on boards
13:00-13:10	Evaluations of the day		
13:10-13:40	Lunch		Take away or eat at the Restaurant
<b>13:40</b>	Bus to Hotels and Free time in the afternoon		
<b>TBC</b>	Bus from Hotels to Les Pensières		
<b>TBC</b>	Dinner upon Registration		Restaurant
<b>TBC</b>	Bus from Les Pensières to Hotels		

## SUNDAY 17 MAY 2026

**TBC** Bus from hotels to Les Pensières (for dinner only)

**TBC** Dinner upon registration Restaurant

**TBC** Bus from Les Pensières to Hotel

# MONDAY 18 MAY 2026

**TBC** Bus from hotels to Les Pensières

09:00-09:10	<b>Ethical considerations in vaccine trials: Recap</b>	<b>Catherine Slack</b> , University of KwaZulu-Natal, South Africa	Charles Mérieux conf. Room
<b>SESSION 8 – DECISION MAKING FOR VACCINES (Part 1/2)</b>			<u>Chair: Louise Henaff</u>
09:10-09:35	<b>33. The decision-making processes for vaccines use:</b> global, regional and local perspectives	<b>Rudzani Muloiwa</b> , University of Cape Town, South Africa	
09:35-09:55	Discussion		Charles Mérieux
09:55-10:20	<b>34. The example of the WHO SAGE decision making processes (GRADE)</b>	<b>Melanie Marti</b> , WHO Geneva, Switzerland	
10:20-10:40	Discussion		
10:40-11:10	Break		Restaurant
11:10-11:35	<b>35. The decision-making processes for vaccines' use:</b> what should experts consider	<b>Kari Johansen</b> , Public Health Agency of Sweden	
11:35-11:55	Discussion		
11:55-12:20	<b>36. The role of health economics (including modelling) as a tool in analyzing vaccine policy options</b>	<b>Marc Brisson</b> , Université de Laval, Canada	Charles Mérieux
12:20-12:40	Discussion		
12:40-12:50	Morning Evaluations		
12:50-13:50	Lunch		Restaurant
13:50-16:00	<b>Small group exercise 5</b>  <b>Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.</b>	<b>7 Groups:</b>  <ul style="list-style-type: none"> <li>• <b>Group 1: Rotavirus:</b> M. Iturriza</li> <li>• <b>Group 2: HPV:</b> K. Senouci</li> <li>• <b>Group 3: Dengue LMICs:</b> H. Nohynek</li> <li>• <b>Group 4: Zoster:</b> K. Johansen</li> <li>• <b>Group 5: Malaria:</b> K. Neuzil</li> <li>• <b>Group 6: RSV Adults:</b> K. Talbot</li> <li>• <b>Group 7: RSV:</b> J. Englund</li> </ul>	Check rooms' assignments on boards
16:00-16:20	Break		Restaurant
<b>SESSION 9 – UPDATES ON VACCINES (part 1/4)</b>			<u>Chair: Anna Durbin</u>
16:20-16:45	<b>37. Polysaccharide and conjugate vaccines</b>	<b>David Goldblatt</b> , University College London, UK (online)	
16:45-17:05	Discussion		
17:05-17:30	<b>38. Pneumococcal conjugate vaccines:</b> the impact of PCV, its introduction in different populations (including adults & children) and the change in PCV valency stereotypes	<b>Keith Klugman</b> , Gates Foundation, USA (online)	Charles Mérieux conf. Room
17:30-17:50	Discussion		
17:50-18:00	Afternoon evaluations		
18:00-19:00	Book your Mentor		
19:00-20:15	Dinner		Restaurant + O. Doumbo
20:30	Bus to Hotels		

# TUESDAY 19 MAY 2026

**TBC**

Bus from hotels to Les Pensières

<b>SESSION 9 – UPDATES ON VACCINES (part 2/4)</b>			<b>Chair: Anna Durbin</b>
09:00-09:25	<b>39. HPV vaccines</b>	<b>Deborah Watson-Jones</b> , London School of Hygiene and Tropical Medicine & Mwanza Intervention Trials Unit (MITU) Tanzania	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	<b>40. Typhoid vaccines</b>	<b>Kathy Neuzil</b> , Gates Foundation	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	<b>41. Malaria Vaccines</b>	<b>Simon Draper</b> , University of Oxford, UK	
11:25-11:45	Discussion		
11:45-12:10	<b>42. Vaccines against arboviruses (Dengue, Zika, Chikungunya)</b>	<b>Anna Durbin</b> , Johns Hopkins Bloomberg School of Public Health, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo
14:00-14:25	<b>43. Rotavirus and norovirus vaccines</b>	<b>Miren Iturriza</b> , Gates Foundation	
14:25-14:45	Discussion		Charles Mérieux
<b>SESSION 8 – DECISION MAKING FOR VACCINES (Part 2/2)</b>			<b>Chair: Anna Durbin</b>
14:45-15:45	<b>Small group exercise 6</b> Sharing recommendations with the Minister of Health	Restitution of the 7 Groups from Exercise 5	Charles Mérieux
15:45-16:15	Break		Restaurant
<b>SESSION 9 – UPDATES ON VACCINES (part 3/4)</b>			<b>Chair: Anna Durbin</b>
16:15-16:40	<b>44. Annual strain adaptation: the examples of Flu and COVID vaccines</b>	<b>Kanta Subbarao</b> , Université de Laval, Canada	
16:40-17:00	Discussion		
17:00-17:25	<b>45. Combination vaccines</b>	<b>Hanna Nohynek</b> , Finnish Institute for Health and Welfare, Finland	Charles Mérieux
17:25-17:45	Discussion		
17:45-18:10	<b>46. Vaccines for Non-Communicable Diseases</b>	<b>Joachim Hombach</b> , University of Geneva, Switzerland	
18:10-18:30	Discussion		
18:30 - 18:40	Afternoon evaluation		
18:40-19:10	<b>Debate “Mandatory vs voluntary vaccination”</b>	<b>Rudzani Muloiwa &amp; Kathy Neuzil</b>	<b>Nicole Mérieux</b>
19:10-20:40	Aperitive and Dinner		Restaurant + O. Doumbo
20:30	Bus to Hotels		

# WEDNESDAY 20 MAY 2026

**TBC** Bus from Hotels to les Pensières

## SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES

Chair: **Hanna Nohynek**

09:00-09:25	47. RSV and GBS vaccines	Janet Englund, University of Washington/Seattle Children's Hospital Seattle, USA	Charles Mérieux conf. Room
09:25-09:45	Discussion		
09:45-10:10	48. Vaccination and pregnancy and early life	Christiane Eberhardt, University of Geneva, Switzerland	Charles Mérieux
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	49. Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias, Children's Hospital Colorado, USA	Charles Mérieux
11:25-11:45	Discussion		
11:45-12:10	50. Vaccine responses and efficacy in the elderly	Keipp Talbot, Vanderbilt University, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	51. Vaccination in immuno-compromised individuals	Christoph Berger, University of Basel, Switzerland	Charles Mérieux
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:55	Lunch		Restaurant

## 15:00-16:30 PARALLEL SESSIONS (rotation of two 45 min-Sessions)

1. National decision-making for immunization programmes	Louise Henaff, Rudzani Muloiwa, Cape Town University	Check Board for Assignment into group exercises
2. Clinical vaccinology: from Guidelines to Patient Care	Alessandro Diana, Christiane Eberhardt, University Hospitals of Geneva (HUG)	
3. New approaches towards vaccination e-registries	Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden	
4. Monitoring immunization program performance	Jan Grevendonk, WHO Geneva	
5. Global and regional data for Global Strategies	Laure Dumolard, WHO Geneva	
6. AEFI causality assessment	Madhav Balakrishnan, WHO, Geneva	

16:30-16:45 Break Restaurant

## SESSION 11 – REACHING SPECIFIC GROUPS (part ½)

Chair: **Kamel Senouci**

16:45-17:10	52. How to better reach the zero-dose or under-vaccinated children in LMICs	Kamel Senouci, University of Geneva	Charles Mérieux conf. Room
17:10-17:30	Discussion		
17:30-17:40	Afternoon evaluations		Restaurant
18:30-20:00	Dinner upon registration		
20:00	Bus to Hotels		

# THURSDAY 21 MAY 2026

**TBC** Bus from hotels to Les Pensières

<b>SESSION 9 – UPDATES ON VACCINES (Part 4/4)</b>			<u>Chair: Edwin Asturias</u>
09:00-09:25	<b>53. Cholera vaccines</b>	<b>Alejandro Cravioto</b> , National Autonomous University of Mexico	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	<b>54. Meningococcal vaccines</b>	<b>Shamez Ladhani</b> , UKHSA, UK	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	<b>55. Tuberculosis vaccines</b>	<b>Helen McShane</b> , University of Oxford, UK	
11:25-11:45	Discussion		Charles Mérieux
<b>SESSION 11 – REACHING SPECIFIC GROUPS (part 2/2)</b>			<u>Chair: Kamel Senouci</u>
11:45-12:10	<b>56. Life-course vaccines: how to better reach individuals from childhood to elderly?</b>	<b>Pierre Vandamme</b> , University of Antwerp, Belgium (online)	
12:10-12:30	Discussion		Charles Mérieux
12:30-12:55	<b>57. The determinants of vaccine acceptance</b>	<b>Eve Dubé</b> , Université de Laval, Canada	
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25 – 14:25	Lunch		Restaurant + O.DUmbo
<b>SESSION 12 – COMMUNICATION AND VACCINE HESITANCY (part ½)</b>			
14:25-15:25	<b>Small group exercise 7: Identifying &amp; Collecting Evidence to advise on demand generation</b>	<b>Eve Dubé, Naveen Thacker, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson</b>	Several rooms: please check on boards
15:25-16:25	<b>Interactive Session 4 and Q&amp;A</b>	<b>Justin Poncet and Darius Beucler</b> , OPSCI, France	Charles Mérieux
16:25-16:35	<b>Vaccination in the face of information chaos: from Analysis to Strategic Response</b>		
16:25-16:35	Afternoon evaluations		
16:35-16:55	Break		Restaurant
<b>16:55</b>	Bus departure from les Pensières to hotels (check board for return bus from hotels to the Menthon Castle)		Meet at the Reception Lobby
<b>18:15</b>	<b>Bus departure from Les Pensières to Château de Menthon Saint Bernard for visit of the castle and Gala Dinner</b>		
<b>22:30 and 00:00</b>	Buses from Château de Menthon to les Pensières & Hotels		

# FRIDAY 22 MAY 2026

**TBC** Bus from hotels to Les Pensières

## SESSION 12: COMMUNICATION AND VACCINE HESITANCY (part 2/2)

Chair:  
Louise Henaff,

09:00-09:20	58. Introduction to Communication Strategy design	Louise Henaff, University of Geneva	Charles Mérieux conf. Room
09:20-10:30	Small Group Exercise 8: Communication strategy design	Justin Poncet, Darius Beucler, Kamel Senouci, Louise Henaff, Eve Dubé, Naveen Thacker	Several rooms: check on boards
10:30-11:00	Break		Restaurant
11:00-11:25	59. Introduction to Empathetic Communication	Philipp Schmid, JITSUVAX, Netherlands	Charles Mérieux
11:25-12:30	Small Group Exercise 9: Empathetic Communication, Role play	Philipp Schmid, Eve Dubé, Alessandro Diana, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson	Several rooms: check on boards

## SESSION 13: INNOVATION ON IMMUNIZATION

Chair:  
Kamel Senouci

12:30-12:55	60. Artificial Intelligence and vaccines	Edwin Asturias, Children's Hospital Colorado, USA	Dr. Charles Mérieux conf. Room
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:40	Lunch		Restaurant + O. Doumbo

## SESSION 14: CLOSING

14:40-15:00	Final evaluation and Post course assessment		Charles Mérieux
15:00-15:45	Diploma ceremony, awarding of CME credits and closure of the course	Kamel Senouci, Director, ADVAC, University of Geneva	
<b>TBC</b>	Bus from Les Pensières to hotels (check boards for Schedule)		

WEDNESDAY 13 MAY 2026

**SESSION 3: VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL**

**Chair: Kamel Senouci,**  
Director  
ADVAC,  
University of  
Geneva

16:45-18:15

**Interactive Session 2**

**From ideas to implementation** - the realities of funding for vaccine research and development in the private sector

**Two 45-minutes sessions (2 groups switching)**

**Group A:** starting with Fiocruz

**Group B:** starting with Luis Jodar

**Luis Jodar, independent expert**

**Rosane Cuber, Bio-Manguinhos Brazil**

Room Charles  
Mérieux

+

Room Nicole  
Mérieux